Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC)

被引：1
|
作者：
Seront, Emmanuel
Rottey, Sylvie
Filleul, Bertrand
Glorieux, Phillipe
Goeminne, Jean Charles.
Vandenbulcke, Jean-Marie
Sautois, Brieuc
Boegner, Petra
Verschaeve, Vincent
Gillain, Aline
Van Maanen, Aline
Machiels, Jean-Pascal H.
机构：
[1] Catholic Univ Louvain, Clin Univ St Luc, Inst Roi Albert II, B-1200 Brussels, Belgium
[2] Ghent Univ Hosp, Ghent, Belgium
[3] Hop De Jolimont, Haine St Paul, Belgium
[4] Clin Sud Luxembourg, Robelmont, Belgium
[5] Clin Maternite St Elisabeth, Namur, Belgium
[6] Roseau Hosp Med Sociale, Tournai, Belgium
[7] CHU Sart Tilman, B-4000 Liege, Belgium
[8] Ctr Hosp Epicura, Baudour, Belgium
[9] Grand Hop Charleroi, Charleroi, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e15535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15535
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma
    Seront, Emmanuel
    Rottey, Sylvie
    Filleul, Bertrand
    Glorieux, Philippe
    Goeminne, Jean-Charles
    Verschaeve, Vincent
    Vandenbulcke, Jean-Marie
    Sautois, Brieuc
    Boegner, Petra
    Gillain, Aline
    van Maanen, Aline
    Machiels, Jean-Pascal
    BJU INTERNATIONAL, 2016, 118 (03) : 408 - 415
  • [2] A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
    Carlo, Maria I.
    Molina, Ana M.
    Lakhman, Yulia
    Patil, Sujata
    Woo, Kaitlin
    DeLuca, John
    Lee, Chung-Han
    Hsieh, James J.
    Feldman, Darren R.
    Motzer, Robert J.
    Voss, Amartin H.
    ONCOLOGIST, 2016, 21 (07): : 787 - 788
  • [3] The Dual PI3K/mTOR Inhibitor BEZ235 Is Effective in Lung Cancer Cell Lines
    Herrera, Vivian Arrias
    Zeindl-Eberhart, Evelyn
    Jung, Andreas
    Huber, Rudolf Maria
    Bergner, Albrecht
    ANTICANCER RESEARCH, 2011, 31 (03) : 849 - 854
  • [4] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Wise-Draper, Trisha M.
    Moorthy, Ganesh
    Salkeni, Mohamad A.
    Karim, Nagla Abdel
    Thomas, Hala Elnakat
    Mercer, Carol A.
    Beg, M. Shalaan
    O'Gara, Sue
    Olowokure, Olugbenga
    Fathallah, Hassana
    Kozma, Sara C.
    Thomas, George
    Rixe, Olivier
    Desai, Pankaj
    Morris, John C.
    TARGETED ONCOLOGY, 2017, 12 (03) : 323 - 332
  • [5] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Trisha M. Wise-Draper
    Ganesh Moorthy
    Mohamad A. Salkeni
    Nagla Abdel Karim
    Hala Elnakat Thomas
    Carol A. Mercer
    M. Shalaan Beg
    Sue O’Gara
    Olugbenga Olowokure
    Hassana Fathallah
    Sara C. Kozma
    George Thomas
    Olivier Rixe
    Pankaj Desai
    John C. Morris
    Targeted Oncology, 2017, 12 : 323 - 332
  • [6] A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
    Wei, Xiao X.
    Hsieh, Andrew C.
    Kim, Won
    Friedlander, Terence
    Lin, Amy M.
    Louttit, Mirela
    Ryan, Charles J.
    ONCOLOGIST, 2017, 22 (05): : 503 - +
  • [7] Radiation Sensitization of HNSCC Cells by the dual PI3K / mTOR Inhibitor BEZ235 as a function of the Cell Cycle
    Brandt, F. W.
    Balzer, V
    Dreffke, K.
    Wittig, A.
    Dikomey, E.
    Arenz, A.
    Schoetz, U.
    Engenhart-Cabillic, R.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S165 - S165
  • [8] The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors
    Arkenau, Hendrik-Tobias
    Jones, Suzanne Fields
    Kurkjian, Carla
    Infante, Jeffrey R.
    Pant, Shubham
    Burris, Howard A.
    Moore, Kathleen N.
    McMeekin, D. Scott
    Greco, Frank A.
    Ramsey, Sara
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
    Baumann, Philipp
    Mandl-Weber, Sonia
    Oduncu, Fuat
    Schmidmaier, Ralf
    EXPERIMENTAL CELL RESEARCH, 2009, 315 (03) : 485 - 497
  • [10] A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
    Johanna C. Bendell
    Carla Kurkjian
    Jeffrey R. Infante
    Todd M. Bauer
    Howard A. Burris
    F. Anthony Greco
    Kent C. Shih
    Dana S. Thompson
    Cassie M. Lane
    Lindsey H. Finney
    Suzanne F. Jones
    Investigational New Drugs, 2015, 33 : 463 - 471
12345